NASDAQ:ADVMAdverum Biotechnologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adverum Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.20 +0.56 (+3.17 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$17.61Now: $18.20▼$18.3750-Day Range$16.65MA: $20.03▼$25.6452-Week Range$4.96Now: $18.20▼$26.98Volume463,906 shsAverage Volume1.38 million shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/ABeta2.06 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAdverum Biotechnologies has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 8 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.63, Adverum Biotechnologies has a potential upside of 29.7% from its current price of $18.22.Amount of Analyst CoverageAdverum Biotechnologies has only been the subject of 4 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAdverum Biotechnologies has received 336 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdverum Biotechnologies has received 368 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdverum Biotechnologies has received 52.27% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote “Outperform” if you believe ADVM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,528,225.00 in company stock.Percentage Held by InsidersOnly 12.40% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions99.67% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($1.23) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -16.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -16.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 6.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADVM Previous Symbol CUSIPN/A CIK1501756 Webwww.adverum.com Phone650-656-9323Debt Debt-to-Equity Ratio0.09 Current Ratio17.92 Quick Ratio17.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$250,000.00 Price / Sales5,845.55 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book6.72Profitability EPS (Most Recent Fiscal Year)($1.01) Net Income$-64,490,000.00 Net MarginsN/A Return on Equity-35.53% Return on Assets-29.55%Miscellaneous Employees82 Outstanding Shares80,296,000Market Cap$1.46 billion Next Earnings Date8/10/2020 (Confirmed) OptionableOptionable $18.20 +0.56 (+3.17 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ADVM News and Ratings via Email Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions How has Adverum Biotechnologies' stock been impacted by COVID-19 (Coronavirus)? Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADVM stock has increased by 96.5% and is now trading at $18.20. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Adverum Biotechnologies? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 sell rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adverum Biotechnologies. When is Adverum Biotechnologies' next earnings date? Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Adverum Biotechnologies. How can I listen to Adverum Biotechnologies' earnings call? Adverum Biotechnologies will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies Inc (NASDAQ:ADVM) released its earnings results on Thursday, May, 28th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. View Adverum Biotechnologies' earnings history. What price target have analysts set for ADVM? 9 Wall Street analysts have issued 1-year price targets for Adverum Biotechnologies' stock. Their forecasts range from $17.00 to $36.00. On average, they anticipate Adverum Biotechnologies' share price to reach $23.63 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price. View analysts' price targets for Adverum Biotechnologies. Has Adverum Biotechnologies been receiving favorable news coverage? Media stories about ADVM stock have trended somewhat negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adverum Biotechnologies earned a news impact score of -1.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View the latest news about Adverum Biotechnologies. Who are some of Adverum Biotechnologies' key competitors? Some companies that are related to Adverum Biotechnologies include Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Twist Bioscience (TWST), Fate Therapeutics (FATE), Denali Therapeutics (DNLI) and Immunovant (IMVT). View all competitors. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Endologix (ELGX), Immunomedics (IMMU), Amarin (AMRN), Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG) and Crispr Therapeutics (CRSP). Who are Adverum Biotechnologies' key executives? Adverum Biotechnologies' management team includes the following people: Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 52)Dr. Mitchell H. Finer, Co-Founder & Director (Age 60)Dr. Amber Salzman, Consultant (Age 57)Ms. Leone D. Patterson, CEO & Director (Age 56)Mr. Thomas Leung, Chief Financial Officer What is Adverum Biotechnologies' stock symbol? Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM." Who are Adverum Biotechnologies' major shareholders? Adverum Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional investors include Versant Venture Management LLC (8.72%), UBS Group AG (2.07%), Rhenman & Partners Asset Management AB (0.62%), Assenagon Asset Management S.A. (0.40%), Candriam Luxembourg S.C.A. (0.28%) and Swiss National Bank (0.17%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Leone D Patterson and Mehdi Gasmi. View institutional ownership trends for Adverum Biotechnologies. Which institutional investors are selling Adverum Biotechnologies stock? ADVM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Versant Venture Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, Parallel Advisors LLC, and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Adverum Biotechnologies company stock in the last year include Leone D Patterson, and Mehdi Gasmi. View insider buying and selling activity for Adverum Biotechnologies. Which institutional investors are buying Adverum Biotechnologies stock? ADVM stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Mackay Shields LLC, Candriam Luxembourg S.C.A., Swiss National Bank, Dupont Capital Management Corp, Russell Investments Group Ltd., ProShare Advisors LLC, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for Adverum Biotechnologies. How do I buy shares of Adverum Biotechnologies? Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Adverum Biotechnologies' stock price today? One share of ADVM stock can currently be purchased for approximately $18.20. How big of a company is Adverum Biotechnologies? Adverum Biotechnologies has a market capitalization of $1.46 billion and generates $250,000.00 in revenue each year. The biotechnology company earns $-64,490,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe. What is Adverum Biotechnologies' official website? The official website for Adverum Biotechnologies is www.adverum.com. How can I contact Adverum Biotechnologies? Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
